Blood cancers

Novel agents bring more choice to RRMM treatment

Tuesday, 20 Aug 2019


Development of novel agents and advances in the understanding of the disease biology have improved treatment options for patients with Relapsed Refractory Multiple Myeloma, with tailored therapy now considered the optimal approach.

In this podcast, Doctor Saad Usmani gives his perspectives on managing relapsed refractory disease in this new era of treatment choice.

This podcast was sponsored by Janssen. The content is based on published studies and the opinions of independent experts. The views expressed are not necessarily those of Janssen.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING (available from www.janssen.com.au).

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2023 the limbic